Summit Therapeutics SMMT Other Non-Current Liabilities
Other Non-Current Liabilities at other companies
Other financials
Where this comes from
Reported directly by Summit Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:OtherLiabilitiesNoncurrent.
The official record: Summit Therapeutics’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Summit Therapeutics's other non-current liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Summit Therapeutics's other non-current liabilities?
- Summit Therapeutics (SMMT) reported other non-current liabilities of $1.8M in Q1 2026.
- How has Summit Therapeutics's other non-current liabilities changed year-over-year?
- Summit Therapeutics's other non-current liabilities increased by 5.3% year-over-year, from $1.71M to $1.8M.
- What is the long-term trend for Summit Therapeutics's other non-current liabilities?
- Over 5 years (2020 to 2025), Summit Therapeutics's other non-current liabilities has grown at a -6.1% compound annual growth rate (CAGR), from $2.51M to $1.83M.
- What does other non-current liabilities mean?
- Miscellaneous long-term debts not categorized elsewhere.
- How do you interpret other non-current liabilities?
- Significant increases may warrant investigation into potential off-balance-sheet risks or changes in accounting estimates.
- How does other non-current liabilities compare across companies?
- Varies significantly by company; often contains unique, non-recurring long-term items.